Advertisement
Home Leukemia & Lymphoma Society

Leukemia & Lymphoma Society

MYELOMA 101 – PART II

Redefining Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma Manisha Bhutani, MD, Charlotte, NC Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are considered clinically silent precursor conditions to MM. The overall risk of progression to malignancy is quite low for MGUS at 1% annually, whereas approximately...
COVID-19 Coronavirus Infections Viruses
Zainab Shahid, MD, FACP, and Shaji K. Kumar, MD March 11 marked the one-year anniversary of the World Health Organization declaring the COVID-19 outbreak a global pandemic. A year later, we are still learning the true impact of this pandemic on the delivery of cancer care globally. Clinical data on...
Elisa S. Weiss, PhD, Senior Vice President, Education, Services & Health Research, LLS, New York The Leukemia and Lymphoma Society (LLS) has a number of ongoing initiatives focused on increasing equity in access to care. One of its most widely-recognized programs is Myeloma Link (https://www.lls.org/myeloma-link) launched in 2017. Myeloma is...
Ola Landgren, MD, PhD, Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami Multiple myeloma (MM), the second most common hematologic malignancy, is consistently preceded by the asymptomatic expansion of clonal plasma cells, termed either monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM).1-6 These two clinically defined precursor...
María-Victoria Mateos, MD, PhD, Borja Puertas MD and Veronica González-Calle MD, PhD Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer (Universidad de Salamanca-Consejo Superior de Investigaciones Científicas), CIBERONC, Salamanca, Spain In 2021, the annual congress of the European Hematology Association (EHA)...
Communication between the clinician and patient, as a two-way conversation, clarity on goals for treatment and treatment protocol, patient education, and support from other members of the healthcare team, can all contribute to adherence to therapy and overall quality of life.   To better understand the patient experience, our Editor in-Chief,...
Zainab Shahid, MD, FACP, and Shaji K. Kumar, MD March 11 marked the one-year anniversary of the World Health Organization declaring the COVID-19 outbreak a global pandemic. A year later, we are still learning the true impact of this pandemic on the delivery of cancer care globally. Clinical data on...

MYELOMA 101 – PART I

Incidence, disease presentation, and clinical diagnosis Based on the LLS Professional Education Webcast:Multiple Myeloma: Diagnosis, Treatment, and Side Effects Management Orsi Giricz, PhD, and Saad Usmani, MD Multiple myeloma (MM) is a malignancy of the plasma cells. A plasma cell is a type of white blood cell that develops from activated...
Neha Korde, MD The year of 2020 marked a tumultuous period for the world of medicine, marred with a global pandemic that effectively gripped the global scientific community. Despite all this, the scientific research community continued to make significant strides in the treatment of multiple myeloma (MM), as showcased by...
Peter Voorhees, PhD The promise of the alkylating agent melphalan for the treatment of multiple myeloma (MM) was first documented in 1958 where reduction in tumor burden was noted in three of six patients.1 In 2018, the combination of melphalan, prednisone, bortezomib, and daratumumab received approval from the Food and...